Wyeth-Ayerst Opts For Oxford Molecular's RS3 Discovery System | GenomeWeb

OXFORD--Wyeth-Ayerst Research has signed a deal with Oxford Molecular Group to license and install Oxford's RS3 Discovery client/server information management system enterprise-wide. According to Oxford, the pharmaceutical company will use the system for chemical registration, structure and substructure searching, and integrating biological assay data through a common Oracle-RS3 Discovery server.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.